Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Phase III trial of ruxolitinib plus parsaclisib in treatment-naïve myelofibrosis

Abdulraheem Yacoub • 4 Jun 2021
ASCO 2021 EHA 2021
Myelofibrosis Myeloproliferative Neoplasms Parsaclisib Ruxolitinib

Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, MO, gives an overview of a Phase III randomized double-blind trial (NCT04551066) which will explore ruxolitinib plus parsaclisib in patients with myelofibrosis who are naïve to JAK and PI3K inhibitors. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Abdulraheem Yacoub

2:06
Parsaclisib plus ruxolitinib in myelofibrosis: a promising strategy for treatment-naive patients
Abdulraheem Yacoub • 26 Aug 2022
2:42
The management of advanced phase MPNs
Abdulraheem Yacoub • 26 Aug 2022
4:15
The latest data on momelotinib for MPNs
Abdulraheem Yacoub • 10 Aug 2021
4:11
Novel therapies and combinations for myelofibrosis patients
Abdulraheem Yacoub • 10 Aug 2021

Related Videos

2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
2:45
The addition of venetoclax to HMAs for the treatment of CMML: a retrospective PSM analysis
Douglas Tremblay • 9 Dec 2023
The content of VJHemOnc is intended for healthcare professionals